EUVIMEDEUVIMED entdecken
Open Access

TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial

Noreen S Siddiqi iD

Radiology: Imaging Cancer · 01.03.2026 · 8 (2)

DOI: 10.1148/rycan.269003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiology: Imaging Cancer, erschienen am 01.03.2026. Verfasst von Noreen S Siddiqi. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

ORCID-Profile: Noreen S Siddiqi

Förderung

  • NCI NIH HHS

Zitieren

APA

Siddiqi, N. S. (2026). TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial. Radiology: Imaging Cancer, 8(2). https://doi.org/10.1148/rycan.269003

Vancouver

Siddiqi NS. TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial. Radiology: Imaging Cancer. 2026;8(2). doi:10.1148/rycan.269003

BibTeX
@article{Siddiqi2026,
  author = {Siddiqi, Noreen S},
  title = {TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial},
  journal = {Radiology: Imaging Cancer},
  year = {2026},
  volume = {8},
  number = {2},
  doi = {10.1148/rycan.269003}
}
Kostenlos starten →